Extranodal Natural Killer T-cell Lymphoma

• CLINICAL_TRIALS research · 2025-12-02
  Clinical Trial Update: Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma [EARLY_Phase 1]

  A Phase 1 trial assessing safety and preliminary efficacy of anti-EBV autologous TCR-T cell therapy in relapsed/refractory EBV-positive lymp…

• CLINICAL_TRIALS research · 2025-09-26
  Clinical Trial Update: A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL [Phase 1, Phase 2]

  Clinical trial update for GNC-038 injection in Phase 1/2 studies for relapsed or refractory NK/T-cell lymphoma and Non-Hodgkin lymphoma, wit…

• CLINICAL_TRIALS research · 2025-03-13
  Clinical Trial Update: Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma [Phase 1, Phase 2]

  A Phase 1/2 trial is evaluating the combination of tislelizumab with liposomal mitoxantrone in extranodal natural killer/T-cell lymphoma; th…

• CLINICAL_TRIALS trial_result · 2025-03-13
  Clinical Trial Update: Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma [Phase 1]

  This clinical trial update reports a Phase 1 study evaluating the combination of sintilimab and linperlisib for relapsed or refractory extra…

• CLINICAL_TRIALS research · 2024-10-26
  Clinical Trial Update: PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma [NA]

  This ClinicalTrials.gov update describes a study evaluating PET/MR imaging for staging and efficacy assessment in newly diagnosed Extranodal…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2024-08-27
  Clinical Trial Update: Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL [Phase 2]

  Phase 2 clinical trial evaluating selinexor in combination with an anti-PD-1 antibody and golidocitinib for relapsed/refractory extranodal n…

• CLINICAL_TRIALS trial_result · 2024-06-18
  Clinical Trial Update: A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) [Phase 2]

  A Phase 2 study of CS1001 in relapsed or refractory Extranodal Natural Killer/T-Cell Lymphoma has completed enrollment with results posted o…

• CLINICAL_TRIALS trial_result · 2024-02-13
  Clinical Trial Update: The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma [Phase 3]

  Phase 3 trial comparing chidamide plus anti-PD-1 antibody and peg-aspargase versus DDGP in newly diagnosed stage III-IV extranodal natural k…